This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bollinger, M. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bollinger, M. E.

PEDIATRICS Vol. 104 No. 2 Supplement August 1999, pp. 396

Other Therapies
Benefits of High-Dose Intravenous Immunoglobulin in Patients WithSevere Steroid-Dependent Asthma

Landwehr LP, Jeppson JD, Katlan MG, Chest. 1998; 114:1349-1356 [Medline]

The first 20% of the full text of this article appears below.

Purpose of the Study To determine the efficacy of intravenous gammaglobulin (IVIG) in severe asthma to reduce steroid requirements.

Study Population Eleven severe steroid-dependent asthmatics (5 adolescents, mean age 14 years; 6 adults, mean age 38.5 years) were studied at National Jewish Medical Center in Denver, Colorado. Subjects were excluded if they had cystic fibrosis, chronic bronchitis, acute sinusitis, immunodeficiency, or other chronic diseases besides asthma.

Methods Steroid dependency was defined as requiring >= 0.25 mg/kg/day for a minimum of 2 months before entry into the study and subjects must have had at least one exacerbation of their asthma during the previous 3 months requiring an additional short course of high-dose oral steroids. All subjects had been taking daily or alternate day oral steroids for several years. . . . [Full Text of this Article]